Arrowhead Research traded at $39.99 this Wednesday July 6th, increasing $0.83 or 2.12 percent since the previous trading session. Looking back, over the last four weeks, Arrowhead Research gained 14.62 percent. Over the last 12 months, its price fell by 37.25 percent. Looking ahead, we forecast Arrowhead Research to be priced at 34.99 by the end of this quarter and at 32.22 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Agios Pharmaceuticals 25.35 -0.10 -0.39% -55.38%
Alnylam Pharmaceuticals 150.00 -0.73 -0.48% -13.09%
Anika Therapeutics 22.50 -0.25 -1.10% -48.07%
Arrowhead Research 39.99 0.83 2.12% -37.25%
Bluebird Bio 4.82 -0.23 -4.55% -84.51%
Heron Therapeutics 3.14 0.14 4.67% -77.76%
Intercept Pharmaceuticals 15.29 0.14 0.92% -19.44%
Incyte Corp 79.72 0.47 0.59% -2.93%
Ionis Pharmaceuticals 36.81 -1.04 -2.75% -5.52%
Ligand Pharmaceuticals 95.83 0.40 0.42% -25.68%
Merck & Co 93.13 0.49 0.53% 18.55%
Moderna Inc 159.56 4.02 2.58% -28.09%
Mirati Therapeutics 69.83 -2.13 -2.96% -56.07%
Nektar Therapeutics 3.90 -0.03 -0.76% -76.53%
Novartis 81.89 0.67 0.82% -2.64%
Opko Health 2.74 0.09 3.40% -28.83%
Ultragenyx Pharmaceutical 63.38 -0.42 -0.66% -29.29%
Spectrum Pharmaceuticals 0.81 0.01 1.24% -76.45%
Sarepta Therapeutics 75.97 0.23 0.30% 5.53%
TG Therapeutics 5.29 0.04 0.76% -85.90%
Vertex Pharmaceuticals 291.16 2.18 0.75% 46.32%
Xencor 32.44 1.99 6.54% -4.14%

Indexes Price Day Year
USND 11362 39.61 0.35% -22.52%
US2000 1728 -13.78 -0.79% -23.32%
US400 2279 -13.85 -0.60% -15.05%

Arrowhead Research
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.